267 related articles for article (PubMed ID: 26739060)
1. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
Xu Z; Wang Z; Jia X; Wang L; Chen Z; Wang S; Wang M; Zhang J; Wu M
Cancer Lett; 2016 Mar; 372(1):118-27. PubMed ID: 26739060
[TBL] [Abstract][Full Text] [Related]
2. A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growth.
Jia X; Wang W; Xu Z; Wang S; Wang T; Wang M; Wu M
Sci Rep; 2016 Jun; 6():27985. PubMed ID: 27301650
[TBL] [Abstract][Full Text] [Related]
3. The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models.
Wang S; Zhou R; Sun F; Li R; Wang M; Wu M
Cancer Lett; 2017 Nov; 409():125-136. PubMed ID: 28923397
[TBL] [Abstract][Full Text] [Related]
4. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
[TBL] [Abstract][Full Text] [Related]
5. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
[TBL] [Abstract][Full Text] [Related]
6. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
7. Cross-talk between endothelial cells and tumor via delta-like ligand 4/Notch/PTEN signaling inhibits lung cancer growth.
Ding XY; Ding J; Wu K; Wen W; Liu C; Yan HX; Chen C; Wang S; Tang H; Gao CK; Guo LN; Cao D; Li Z; Feng GS; Wang HY; Xu ZF
Oncogene; 2012 Jun; 31(23):2899-906. PubMed ID: 22002304
[TBL] [Abstract][Full Text] [Related]
8. MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.
Jenkins DW; Ross S; Veldman-Jones M; Foltz IN; Clavette BC; Manchulenko K; Eberlein C; Kendrew J; Petteruti P; Cho S; Damschroder M; Peng L; Baker D; Smith NR; Weir HM; Blakey DC; Bedian V; Barry ST
Mol Cancer Ther; 2012 Aug; 11(8):1650-60. PubMed ID: 22679110
[TBL] [Abstract][Full Text] [Related]
9. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.
Hoey T; Yen WC; Axelrod F; Basi J; Donigian L; Dylla S; Fitch-Bruhns M; Lazetic S; Park IK; Sato A; Satyal S; Wang X; Clarke MF; Lewicki J; Gurney A
Cell Stem Cell; 2009 Aug; 5(2):168-77. PubMed ID: 19664991
[TBL] [Abstract][Full Text] [Related]
10. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
Li JL; Sainson RC; Shi W; Leek R; Harrington LS; Preusser M; Biswas S; Turley H; Heikamp E; Hainfellner JA; Harris AL
Cancer Res; 2007 Dec; 67(23):11244-53. PubMed ID: 18056450
[TBL] [Abstract][Full Text] [Related]
11. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway.
Zhang J; Ye J; Ma D; Liu N; Wu H; Yu S; Sun X; Tse W; Ji C
Carcinogenesis; 2013 Mar; 34(3):667-77. PubMed ID: 23239744
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
Lee D; Kim D; Choi YB; Kang K; Sung ES; Ahn JH; Goo J; Yeom DH; Jang HS; Moon KD; Lee SH; You WK
MAbs; 2016 Jul; 8(5):892-904. PubMed ID: 27049350
[TBL] [Abstract][Full Text] [Related]
13. A monoclonal antibody against human Notch1 ligand-binding domain depletes subpopulation of putative breast cancer stem-like cells.
Sharma A; Paranjape AN; Rangarajan A; Dighe RR
Mol Cancer Ther; 2012 Jan; 11(1):77-86. PubMed ID: 22075160
[TBL] [Abstract][Full Text] [Related]
14. Delta-like ligand 4 regulates vascular endothelial growth factor receptor 2-driven luteal angiogenesis through induction of a tip/stalk phenotype in proliferating endothelial cells.
García-Pascual CM; Zimmermann RC; Ferrero H; Shawber CJ; Kitajewski J; Simón C; Pellicer A; Gómez R
Fertil Steril; 2013 Dec; 100(6):1768-76.e1. PubMed ID: 24074756
[TBL] [Abstract][Full Text] [Related]
15. Delta-like ligand 4-notch blockade and tumor radiation response.
Liu SK; Bham SA; Fokas E; Beech J; Im J; Cho S; Harris AL; Muschel RJ
J Natl Cancer Inst; 2011 Dec; 103(23):1778-98. PubMed ID: 22010178
[TBL] [Abstract][Full Text] [Related]
16. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells.
Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351
[TBL] [Abstract][Full Text] [Related]
17. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
Kim DH; Lee S; Kang HG; Park HW; Lee HW; Kim D; Yoem DH; Ahn JH; Ha E; You WK; Lee SH; Kim SJ; Chun KH
BMB Rep; 2020 Nov; 53(10):533-538. PubMed ID: 32580836
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis.
Yang MH; Zang YS; Huang H; Chen K; Li B; Sun GY; Zhao XW
Curr Cancer Drug Targets; 2014; 14(6):557-66. PubMed ID: 25088040
[TBL] [Abstract][Full Text] [Related]
20. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
Gao W; Jin K; Lan H; Han N; Cao F; Teng L
Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
